These results suggest that the expression of exocrine QSOX2 protein increased in the serum of NSCLC patients, and downregulation of intracellular and extracellular QSOX2 expression was related to the anti-tumor therapy. This evidence concerns the gene QSOX2 and non-small cell lung carcinoma.